{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:31Z","timestamp":1787032891715,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.7759\/cureus.91376","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:18:59Z","timestamp":1756711139000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Intraocular Anti-vascular Endothelial Growth Factor (VEGF) Drug-Associated Adverse Events Using Spontaneous Reporting Databases"],"prefix":"10.7759","author":[{"given":"Mugita","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waranee","family":"Bunchuailua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suang","family":"Rungpragayphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sugishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sineenart","family":"Krichanchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornsak","family":"Sriamornsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein DB","year":"2022","unstructured":"Rein DB, Wittenborn JS, Burke-Conte Z, et al.. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022, 140:1202-8. 10.1001\/jamaophthalmol.2022.4401","journal-title":"JAMA Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-023-00986-9","article-title":"A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification","volume":"67","author":"Matoba R","year":"2023","unstructured":"Matoba R, Morimoto N, Kawasaki R, et al.. A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification. Jpn J Ophthalmol. 2023, 67:346-52. 10.1007\/s10384-023-00986-9","journal-title":"Jpn J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-008-1724-0","article-title":"[Quality of life by limited vision in old age: the example of age-related macula degeneration]","volume":"105","author":"Wahl HW","year":"2008","unstructured":"Wahl HW, Heyl V, Langer N. [Quality of life by limited vision in old age: the example of age-related macula degeneration]. Ophthalmologe. 2008, 105:735-43. 10.1007\/s00347-008-1724-0","journal-title":"Ophthalmologe"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey AK","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, et al.. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018, 71:e1-8. 10.1161\/HYPERTENSIONAHA.117.10271","journal-title":"Hypertension"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara N","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016, 15:385-403. 10.1038\/nrd.2015.17","journal-title":"Nat Rev Drug Discov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"Olsson AK","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006, 7:359-71. 10.1038\/nrm1911","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref7","unstructured":"National Institute of Health Sciences Division of Biological Chemistry and Biologicals. approved biologics. (2025). Accessed: 8 August 2025: https:\/\/www.nihs.go.jp\/dbcb\/approved_biologicals.html."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery RL","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, et al.. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014, 98:1636-41. 10.1136\/bjophthalmol-2014-305252","journal-title":"Br J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003344","article-title":"Changes in systemic levels of vascular endothelial growth factor after intravitreal injection of aflibercept or brolucizumab for neovascular age-related macular degeneration","volume":"42","author":"Angermann R","year":"2022","unstructured":"Angermann R, Huber AL, Nowosielski Y, et al.. Changes in systemic levels of vascular endothelial growth factor after intravitreal injection of aflibercept or brolucizumab for neovascular age-related macular degeneration. Retina. 2022, 42:503-10. 10.1097\/IAE.0000000000003344","journal-title":"Retina"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06755-3","article-title":"Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD","volume":"263","author":"Huber AL","year":"2025","unstructured":"Huber AL, Bauer A, Beirer J, et al.. Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD. Graefes Arch Clin Exp Ophthalmol. 2025, 263:1259-67. 10.1007\/s00417-025-06755-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.07.008","article-title":"Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: a World Health Organization pharmacovigilance study","volume":"132","author":"Yang JM","year":"2025","unstructured":"Yang JM, Jung SY, Kim MS, Lee SW, Yon DK, Shin JI, Lee JY. Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: a World Health Organization pharmacovigilance study. Ophthalmology. 2025, 132:62-78. 10.1016\/j.ophtha.2024.07.008","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.06.039","article-title":"Factors associated with in-hospital mortality in very elderly patients with ischemic stroke: a cohort study","volume":"28","author":"Oliveira AD","year":"2019","unstructured":"Oliveira AD, Andrade-Valen\u00e7a LP, Valen\u00e7a MM. Factors associated with in-hospital mortality in very elderly patients with ischemic stroke: a cohort study. J Stroke Cerebrovasc Dis. 2019, 28:104281. 10.1016\/j.jstrokecerebrovasdis.2019.06.039","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.12.6.723","article-title":"Thresholds in cerebral ischemia - the ischemic penumbra","volume":"12","author":"Astrup J","year":"1981","unstructured":"Astrup J, Siesj\u00f6 BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke. 1981, 12:723-5. 10.1161\/01.str.12.6.723","journal-title":"Stroke"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000196957.55928.ab","article-title":"Time is brain-quantified","volume":"37","author":"Saver JL","year":"2006","unstructured":"Saver JL. Time is brain-quantified. Stroke. 2006, 37:263-6. 10.1161\/01.STR.0000196957.55928.ab","journal-title":"Stroke"},{"key":"ref15","unstructured":"Pharmaceuticals and Medical Devices Agency. (2025). Accessed. 6 August 2025: http:\/\/www.pmda.go.jp."},{"key":"ref16","unstructured":"Notice of discontinuation of Macugen\u00ae intravitreal injection kit 0.3 mg. (2019). Accessed. 6 August 2025: https:\/\/www.bausch.co.jp\/ja-jp\/our-company\/newsroom\/2019\/mar-1\/."},{"key":"ref17","unstructured":"Welcome to MedDRA. (2025). Accessed. 6 August 2025: https:\/\/www.meddra.org\/."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek EP","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002, 11:3-10. 10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref19","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). product information for aflibercept. (2024). Accessed: 6 August 2025: https:\/\/www.info.pmda.go.jp\/go\/pack\/1319405A1027_1_16\/."},{"key":"ref20","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). product information for ranibizumab. (2024). Accessed: 6 August 2025: https:\/\/www.info.pmda.go.jp\/go\/pack\/1319403A1036_1_10\/."},{"key":"ref21","unstructured":"Beovu intravitreal injection kit 120mg\/mL. (2025). Accessed. 6 August 2025: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/300242_1319406G1024_1_05."},{"key":"ref22","unstructured":"Baby Smo intravitreal injection solution 120 mg\/mL \/ baby Smo intravitreal injection kit 120 mg\/mL. (2025). Accessed. 6 August 2025: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/450045_1319408A1020_1_06."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.30.17629","article-title":"The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis","volume":"271","author":"Clauss M","year":"1996","unstructured":"Clauss M, Weich H, Breier G, Knies U, R\u00f6ckl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996, 271:17629-34. 10.1074\/jbc.271.30.17629","journal-title":"J Biol Chem"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(20000115)85:2<281::aid-ijc21>3.0.co;2-3","article-title":"Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis","volume":"85","author":"Zanetta L","year":"2000","unstructured":"Zanetta L, Marcus SG, Vasile J, et al.. Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer. 2000, 85:281-8. 10.1002\/(sici)1097-0215(20000115)85:2&lt;281::aid-ijc21&gt;3.0.co;2-3","journal-title":"Int J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.17.9709","article-title":"Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells","volume":"270","author":"Mandriota SJ","year":"1995","unstructured":"Mandriota SJ, Seghezzi G, Vassalli JD, et al.. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem. 1995, 270:9709-16. 10.1074\/jbc.270.17.9709","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291x(91)91276-i","article-title":"Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells","volume":"181","author":"Pepper MS","year":"1991","unstructured":"Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991, 181:902-6. 10.1016\/0006-291x(91)91276-i","journal-title":"Biochem Biophys Res Commun"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(97)00049-1","article-title":"Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening","volume":"29","author":"Van Belle E","year":"1997","unstructured":"Van Belle E, Tio FO, Chen D, Maillard L, Chen D, Kearney M, Isner JM. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol. 1997, 29:1371-9. 10.1016\/s0735-1097(97)00049-1","journal-title":"J Am Coll Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee S","year":"2007","unstructured":"Lee S, Chen TT, Barber CL, et al.. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007, 130:691-703. 10.1016\/j.cell.2007.06.054","journal-title":"Cell"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker AH","year":"2016","unstructured":"van den Meiracker AH, Danser AH. Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition. Hypertension. 2016, 68:17-23. 10.1161\/HYPERTENSIONAHA.116.07618","journal-title":"Hypertension"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.11.003","article-title":"Hypertension and cardiovascular risk: general aspects","volume":"129","author":"Kjeldsen SE","year":"2018","unstructured":"Kjeldsen SE. Hypertension and cardiovascular risk: general aspects. Pharmacol Res. 2018, 129:95-9. 10.1016\/j.phrs.2017.11.003","journal-title":"Pharmacol Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04368.x","article-title":"Vascular endothelial growth factor confers endothelial resistance to apoptosis through poly(ADP-ribose) polymerase","volume":"9","author":"H\u00f6rmann M","year":"2011","unstructured":"H\u00f6rmann M, Mey L, Kharip Z, et al.. Vascular endothelial growth factor confers endothelial resistance to apoptosis through poly(ADP-ribose) polymerase. J Thromb Haemost. 2011, 9:1391-403. 10.1111\/j.1538-7836.2011.04368.x","journal-title":"J Thromb Haemost"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura M","year":"2015","unstructured":"Nakamura M, Umetsu R, Abe J, et al.. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci. 2015, 1:34. 10.1186\/s40780-015-0035-2","journal-title":"J Pharm Health Care Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-021-00513-x","article-title":"Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database","volume":"22","author":"Nakao S","year":"2021","unstructured":"Nakao S, Hasegawa S, Umetsu R, et al.. Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database. BMC Pharmacol Toxicol. 2021, 22:47. 10.1186\/s40360-021-00513-x","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14342","article-title":"Reporting rates of adverse reactions to specialty care medicines exhibit a direct positive correlation with patient exposure: a lack of evidence for the Weber effect","volume":"86","author":"Modgill V","year":"2020","unstructured":"Modgill V, Dormegny L, Lewis DJ. Reporting rates of adverse reactions to specialty care medicines exhibit a direct positive correlation with patient exposure: a lack of evidence for the Weber effect. Br J Clin Pharmacol. 2020, 86:2393-403. 10.1111\/bcp.14342","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/392657-evaluation-of-intraocular-anti-vascular-endothelial-growth-factor-vegf-drug-associated-adverse-events-using-spontaneous-reporting-databases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:19:01Z","timestamp":1756711141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/392657-evaluation-of-intraocular-anti-vascular-endothelial-growth-factor-vegf-drug-associated-adverse-events-using-spontaneous-reporting-databases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.91376","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}